Suppression of premature termination codons as a therapeutic approach

Critical Reviews in Biochemistry and Molecular Biology

Volumn 47, Issue 5, 2012, Pages 444-463

  Keeling, Kim M ^a,b   Wang, Dan ^a,c   Conard, Sara E ^a   Bedwell, David M ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Nonsense mutations; Premature termination codons; Suppression therapy; Translation termination

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC G 418; ARIKACE; ATALUREN; CAFFEINE; DYSTROPHIN; GENTAMICIN; IVACAFTOR; LIPOSOME; LUMACAFTOR; NEGAMYCIN; PAROMOMYCIN; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

BECKER MUSCULAR DYSTROPHY; CYSTIC FIBROSIS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; GENETIC DISORDER; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; NONSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA TRANSLATION; STOP CODON;

AMINOGLYCOSIDES; ANIMALS; CLINICAL TRIALS AS TOPIC; CODON, NONSENSE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC DISEASES, INBORN; HUMANS; MICE; NONSENSE MEDIATED MRNA DECAY; PEPTIDE CHAIN TERMINATION, TRANSLATIONAL; PHENOTYPE; PROTEIN BIOSYNTHESIS; PROTEIN SYNTHESIS INHIBITORS;

MAMMALIA;

EID: 84865507065     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2012.694846     Document Type: Review

References (169)

1. Aldenhoven M, Boelens JJ, de Koning TJ. 2008. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 14:485-498. (Pubitemid 351494741)
2. Ali BH, Al Za'abi M, Blunden G, Nemmar A. 2011. Experimental gentamicin nephrotoxicity and agents that modify it: A mini-review of recent research. Basic Clin Pharmacol Toxicol 109:225-232.
3. Alkalaeva EZ, Pisarev AV, Frolova LY, Kisselev LL, Pestova TV. 2006. In vitro reconstitution of eukaryotic translation reveals cooperativity between release factors eRF1 and eRF3. Cell 125:1125-1136. (Pubitemid 43866201)
4. Amaral MD. 2005. Processing of CFTR: Traversing the cellular maze-how much CFTR needs to go through to avoid cystic fibrosis? Pediatr Pulmonol 39:479-491. (Pubitemid 40696318)
5. Amrani N, Ganesan R, Kervestin S, Mangus DA, Ghosh S, Jacobson A. 2004. A faux 3'-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay. Nature 432:112-118. (Pubitemid 39490837)
6. Arakawa M, Shiozuka M, Nakayama Y, Hara T, Hamada M, Kondo S, Ikeda D, Takahashi Y, Sawa R, Nonomura Y, Sheykholeslami K, Kondo K, Kaga K, Kitamura T, Suzuki-Miyagoe Y, Takeda S, Matsuda R. 2003. Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice. J Biochem 134:751-758. (Pubitemid 38031275)
7. Auld DS, Thorne N, Maguire WF, Inglese J. 2009. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci USA 106:3585-3590.
8. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. 1999. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104:375-381. (Pubitemid 29534321)
9. Beauchamp D, Laurent G, Maldague P, Abid S, Kishore BK, Tulkens PM. 1990. Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-l-aspartic acid. J Pharmacol Exp Ther 255:858-866.
10. Beauchamp D, Labrecque G. 2001. Aminoglycoside nephrotoxicity: Do time and frequency of administration matter? Curr Opin Crit Care 7:401-408. (Pubitemid 34020403)
11. Bhuvanagiri M, Schlitter AM, Hentze MW, Kulozik AE. 2010. NMD: RNA biology meets human genetic medicine. Biochem J 430:365-377.
12. Bonetti B, Fu L, Moon J, Bedwell DM. 1995. The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J Mol Biol 251:334-345.
13. Brendel C, Belakhov V, Werner H, Wegener E, Gärtner J, Nudelman I, Baasov T, Huppke P. 2011. Readthrough of nonsense mutations in Rett syndrome: Evaluation of novel aminoglycosides and generation of a new mouse model. J Mol Med 89:389-398.
14. Brooks DA. 2002. α-L-iduronidase and enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Biol Ther 2:967-976. (Pubitemid 36033261)
15. Brown CM, Stockwell PA, Trotman CN, Tate WP. 1990. Sequence analysis suggests that tetra-nucleotides signal the termination of protein synthesis in eukaryotes. Nucleic Acids Res 18:6339-6345.
16. Capecchi MR. 1967. Polypeptide chain termination in vitro: Isolation of a release factor. Proc Natl Acad Sci USA 58:1144-1151.
17. Caskey CT, Beaudet AL, Scolnick EM, Rosman M. 1971. Hydrolysis of fMet-tRNA by peptidyl transferase. Proc Natl Acad Sci USA 68:3163-3167.
18. Cassan M, Rousset JP. 2001. UAG readthrough in mammalian cells: Effect of upstream and downstream stop codon contexts reveal different signals. BMC Mol Biol 2:3.
19. Chamberlain J. 1997. Dystrophin levels required for genetic correction of Duchenne Muscular Dystrophy. Basic Appl Myol 7:251-255.
20. Chang CW, Hui Y, Elchert B, Wang J, Li J, Rai R. 2002. Pyranmycins, a novel class of aminoglycosides with improved acid stability: The SAR of D-pyranoses on ring III of pyranmycin. Org Lett 4:4603-4606.
21. Clancy JP, Bebök Z, Ruiz F, King C, Jones J, Walker L, Greer H, Hong J, Wing L, Macaluso M, Lyrene R, Sorscher EJ, Bedwell DM. 2001. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 163:1683-1692. (Pubitemid 32578776)
22. Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, Mayer-Hamblett N, Ramsey B. 2007. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 37:57-66. (Pubitemid 46999537)
23. Cosson B, Couturier A, Chabelskaya S, Kiktev D, Inge-Vechtomov S, Philippe M, Zhouravleva G. 2002. Poly(A)-binding protein acts in translation termination via eukaryotic release factor 3 interaction and does not influence [PSI(+)] propagation. Mol Cell Biol 22:3301-3315. (Pubitemid 34453972)
24. Cuthbert AW. 2011. New horizons in the treatment of cystic fibrosis. Br J Pharmacol 163:173-183.
25. Dalphin ME, Stockwell PA, Tate WP, Brown CM. 1999. TransTerm, the translational signal database, extended to include full coding sequences and untranslated regions. Nucleic Acids Res 27:293-294. (Pubitemid 29209464)
26. Darrat I, Ahmad N, Seidman K, Seidman MD. 2007. Auditory research involving antioxidants. Curr Opin Otolaryngol Head Neck Surg 15:358-363. (Pubitemid 47373984)
27. Davidson DJ, Rolfe M. 2001. Mouse models of cystic fibrosis. Trends Genet 17:S29-S37. (Pubitemid 32918309)
28. De Broe ME, Paulus GJ, Verpooten GA, Roels F, Buyssens N, Wedeen R, Van Hoof F, Tulkens PM. 1984. Early effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney Int 25:643-652. (Pubitemid 14079959)
29. Drulis-Kawa Z, Dorotkiewicz-Jach A. 2010. Liposomes as delivery systems for antibiotics. Int J Pharm 387:187-198.
30. Du M, Jones JR, Lanier J, Keeling KM, Lindsey JR, Tousson A, Bebök Z, Whitsett JA, Dey CR, Colledge WH, Evans MJ, Sorscher EJ, Bedwell DM. 2002. Aminoglycoside suppression of a premature stop mutation in a Cftr-/-mouse carrying a human CFTR-G542X transgene. J Mol Med 80:595-604.
31. Du M, Keeling KM, Fan L, Liu X, Kovaçs T, Sorscher E, Bedwell DM. 2006. Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J Mol Med 84:573-582. (Pubitemid 43992849)
32. Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM. 2008. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 105:2064-2069. (Pubitemid 351439465)
33. Du L, Damoiseaux R, Nahas S, Gao K, Hu H, Pollard JM, Goldstine J, Jung ME, Henning SM, Bertoni C, Gatti RA. 2009a. Nonaminoglycoside compounds induce readthrough of nonsense mutations. J Exp Med 206:2285-2297.
34. Du M, Keeling KM, Fan L, Liu X, Bedwell DM. 2009b. Poly-l-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model. J Biol Chem 284:6885-6892.
35. Dunant P, Walter MC, Karpati G, Lochmüller H. 2003. Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 27:624-627. (Pubitemid 36523523)
36. Dunkle JA, Cate JH. 2010. Ribosome structure and dynamics during translocation and termination. Annu Rev Biophys 39:227-244.
37. Durand S, Cougot N, Mahuteau-Betzer F, Nguyen CH, Grierson DS, Bertrand E, Tazi J, Lejeune F. 2007. Inhibition of nonsensemediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies. J Cell Biol 178:1145-1160. (Pubitemid 47480223)
38. Elchert B, Li J, Wang J, Hui Y, Rai R, Ptak R, Ward P, Takemoto JY, Bensaci M, Chang CW. 2004. Application of the synthetic aminosugars for glycodiversification: Synthesis and antimicrobial studies of pyranmycin. J Org Chem 69:1513-1523. (Pubitemid 38280396)
39. Fairclough RJ, Bareja A, Davies KE. 2011. Progress in therapy for Duchenne muscular dystrophy. Exp Physiol 96:1101-1113.
40. Fan-Minogue H, Bedwell DM. 2008. Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity. RNA 14:148-157.
41. Fan-Minogue H, Du M, Pisarev AV, Kallmeyer AK, Salas-Marco J, Keeling KM, Thompson SR, Pestova TV, Bedwell DM. 2008. Distinct eRF3 requirements suggest alternate eRF1 conformations mediate peptide release during eukaryotic translation termination. Mol Cell 30:599-609. (Pubitemid 351755058)
42. Fearon K, McClendon V, Bonetti B, Bedwell DM. 1994. Premature translation termination mutations are efficiently suppressed in a highly conserved region of yeast Ste6p, a member of the ATP-binding cassette (ABC) transporter family. J Biol Chem 269:17802-17808. (Pubitemid 24206165)
43. Finkel RS. 2010. Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: Aminoglycosides and ataluren (PTC124). J Child Neurol 25:1158-1164.
44. Fourmy D, Recht MI, Blanchard SC, Puglisi JD. 1996. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 274:1367-1371. (Pubitemid 26391459)
45. Freistroffer DV, Kwiatkowski M, Buckingham RH, Ehrenberg M. 2000. The accuracy of codon recognition by polypeptide release factors. Proc Natl Acad Sci USA 97:2046-2051. (Pubitemid 30134019)
46. Frolova L, Le Goff X, Rasmussen HH, Cheperegin S, Drugeon G, Kress M, Arman I, Haenni AL, Celis JE, Philippe M. 1994. A highly conserved eukaryotic protein family possessing properties of polypeptide chain release factor. Nature 372:701-703.
47. Frolova L, Le Goff X, Zhouravleva G, Davydova E, Philippe M, Kisselev L. 1996. Eukaryotic polypeptide chain release factor eRF3 is an eRF1-and ribosome-dependent guanosine triphosphatase. RNA 2:334-341. (Pubitemid 26371285)
48. Gilbert DN, Wood CA, Kohlhepp SJ, Kohnen PW, Houghton DC, Finkbeiner HC, Lindsley J, Bennett WM. 1989. Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity. J Infect Dis 159:945-953. (Pubitemid 19113082)
49. Goldmann T, Rebibo-Sabbah A, Overlack N, Nudelman I, Belakhov V, Baasov T, Ben-Yosef T, Wolfrum U, Nagel-Wolfrum K. 2010. Beneficial read-through of a USH1C nonsense mutation by designed aminoglycoside NB30 in the retina. Invest Ophthalmol Vis Sci 51:6671-6680.
50. Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K. 2011. PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C. Hum Gene Ther 22:537-547.
51. Gorini L, Kataja E. 1964. Phenotypic repair by streptomycin of defective genotypes in E. Coli. Proc Natl Acad Sci USA 51:487-493.
52. Guan MX, Fischel-Ghodsian N, Attardi G. 2000. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet 9:1787-1793. (Pubitemid 30608612)
53. Guthrie OW. 2008. Aminoglycoside induced ototoxicity. Toxicology 249:91-96.
54. Hirawat S, Northcutt VJ, Welch EM, Elfring GL, Hwang S, Almstead NG, Ju W, Miller LL. 2004. Phase 1 safety and PK study of PTC124 for nonsense-mutation suppression therapy of cystic fibrosis. Pediatric Pulmonology 38:248.
55. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL. 2007. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single-and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47:430-444. (Pubitemid 46465953)
56. Hirokawa G, Nijman RM, Raj VS, Kaji H, Igarashi K, Kaji A. 2005. The role of ribosome recycling factor in dissociation of 70S ribosomes into subunits. RNA 11:1317-1328. (Pubitemid 41132402)
57. Hoshino S, Imai M, Kobayashi T, Uchida N, Katada T. 1999. The eukaryotic polypeptide chain releasing factor (eRF3/GSPT) carrying the translation termination signal to the 3'-Poly(A) tail of mRNA. Direct association of erf3/GSPT with polyadenylatebinding protein. J Biol Chem 274:16677-16680.
58. Hulka GF, Prazma J, Brownlee RE, Pulver S, Pillsbury HC. 1993. Use of poly-l-aspartic acid to inhibit aminoglycoside cochlear ototoxicity. Am J Otol 14:352-356. (Pubitemid 23246611)
59. Huth ME, Ricci AJ, Cheng AG. 2011. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol 2011:937861.
60. Hwang J, Maquat LE. 2011. Nonsense-mediated mRNA decay (NMD) in animal embryogenesis: To die or not to die, that is the question. Curr Opin Genet Dev 21:422-430.
61. Inglese J, Thorne N, Auld DS. 2009. Reply to Peltz et al: Post-translational stabilization of the firefly luciferase reporter by PTC124 (Ataluren). Proc Natl Acad Sci USA 106:E65.
62. Isken O, Maquat LE. 2007. Quality control of eukaryotic mRNA: Safeguarding cells from abnormal mRNA function. Genes Dev 21:1833-1856. (Pubitemid 47204924)
63. Isken O, Maquat LE. 2008. The multiple lives of NMD factors: Balancing roles in gene and genome regulation. Nat Rev Genet 9:699-712.
64. Jackson RJ, Hellen CU, Pestova TV. 2012. Termination and posttermination events in eukaryotic translation. Adv Protein Chem Struct Biol 86:45-93.
65. Jin H, Kelley AC, Loakes D, Ramakrishnan V. 2010. Structure of the 70S ribosome bound to release factor 2 and a substrate analog provides insights into catalysis of peptide release. Proc Natl Acad Sci USA 107:8593-8598.
66. Jung ME, Ku JM, Du L, Hu H, Gatti RA. 2011. Synthesis and evaluation of compounds that induce readthrough of premature termination codons. Bioorg Med Chem Lett 21:5842-5848.
67. Kandasamy J, Atia-Glikin D, Belakhov V, Baasov T. 2011. Repairing faulty genes by aminoglycosides: Identification of new pharmacophore with enhanced suppression of disease-causing nonsense mutations. Med Chem Commun 2:165-171.
68. Kashima I, Yamashita A, Izumi N, Kataoka N, Morishita R, Hoshino S, Ohno M, Dreyfuss G, Ohno S. 2006. Binding of a novel SMG-1-UPF1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers UPF1 phosphorylation and nonsense-mediated mRNA decay. Genes Dev 20:355-367. (Pubitemid 43200289)
69. Kawamoto K, Sha SH, Minoda R, Izumikawa M, Kuriyama H, Schacht J, Raphael Y. 2004. Antioxidant gene therapy can protect hearing and hair cells from ototoxicity. Mol Ther 9:173-181. (Pubitemid 38256543)
70. Keeling KM. (2000). Suppression of premature stop mutations using aminoglycosides (PhD Thesis). Birmingham: University of Alabama at Birmingham.
71. Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. 2001. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of α-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 10:291-299. (Pubitemid 32123987)
72. Keeling KM, Bedwell DM. (2010). Recoding therapies for genetic diseases. In: Atkins JF, Gesteland RF, (eds). Recoding: Expansion of Decoding Rules Enriches Gene Expression. New York: Springer Publishing, 123-142.
73. Keeling KM, Bedwell DM. 2011. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases. Wiley Interdiscip Rev RNA 2:837-852.
74. Kerem E. 2004. Pharmacologic therapy for stop mutations: How much CFTR activity is enough? Curr Opin Pulm Med 10:547-552. (Pubitemid 39441452)
75. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M. 2008. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial. Lancet 372:719-727.
76. Kim Chiaw P, Eckford PD, Bear CE. 2011. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy. Essays Biochem 50:233-248.
77. Kishore BK, Ibrahim S, Lambricht P, Laurent G, Maldague P, Tulkens PM. 1992. Comparative assessment of poly-l-aspartic and poly-l-glutamic acids as protectants against gentamicininduced renal lysosomal phospholipidosis, phospholipiduria and cell proliferation in rats. J Pharmacol Exp Ther 262:424-432.
78. Korostelev A, Asahara H, Lancaster L, Laurberg M, Hirschi A, Zhu J, Trakhanov S, Scott WG, Noller HF. 2008. Crystal structure of a translation termination complex formed with release factor RF2. Proc Natl Acad Sci USA 105:19684-19689.
79. Korostelev A, Zhu J, Asahara H, Noller HF. 2010. Recognition of the amber UAG stop codon by release factor RF1. EMBO J 29:2577-2585.
80. Korostelev AA. 2011. Structural aspects of translation termination on the ribosome. RNA 17:1409-1421.
81. Kramer EB, Vallabhaneni H, Mayer LM, Farabaugh PJ. 2010. A comprehensive analysis of translational missense errors in the yeast Saccharomyces cerevisiae. RNA 16:1797-1808.
82. Laurberg M, Asahara H, Korostelev A, Zhu J, Trakhanov S, Noller HF. 2008. Structural basis for translation termination on the 70S ribosome. Nature 454:852-857.
83. Laurent G, Carlier MB, Rollman B, Van Hoof F, Tulkens P. 1982. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: In vitro and in vivo studies with gentamicin and amikacin. Biochem Pharmacol 31:3861-3870. (Pubitemid 13218461)
84. Lederberg EM, Cavalli-Sforza L, Lederberg J. 1964. Interaction of streptomycin and a suppressor for galactose fermentation in E. Coli K-12. Proc Natl Acad Sci USA 51:678-682.
85. Li J, Wang J, Czyryca PG, Chang H, Orsak TW, Evanson R, Chang CW. 2004. Application of glycodiversification: Expedient synthesis and antibacterial evaluation of a library of kanamycin B analogues. Org Lett 6:1381-1384. (Pubitemid 38626309)
86. Liang H, Cavalcanti AR, Landweber LF. 2005. Conservation of tandem stop codons in yeasts. Genome Biol 6:R31.
87. Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, Yaacov Y, Virgilis D, Neu-Yilik G, Kulozik AE, Kerem E, Kerem B. 2007. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 117:683-692. (Pubitemid 46348526)
88. Linde L, Kerem B. 2008. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 24:552-563.
89. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. 2011. New insights into the mechanism of aminoglycoside nephrotoxicity: An integrative point of view. Kidney Int 79:33-45.
90. Lynch SR, Puglisi JD. 2001. Structure of a eukaryotic decoding region A-site RNA. J Mol Biol 306:1023-1035. (Pubitemid 33030003)
91. Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, Al-Dahhak R, Lewis S, Shilling CJ, Kota J, Serrano-Munuera C, Hayes J, Mahan JD, Campbell KJ, Banwell B, Dasouki M, Watts V, Sivakumar K, Bien-Willner R, Flanigan KM, Sahenk Z, Barohn RJ, Walker CM, Mendell JR. 2010. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 67:771-780.
92. Manuvakhova M, Keeling K, Bedwell DM. 2000. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6:1044-1055. (Pubitemid 30471140)
93. Martin R, Mogg AE, Heywood LA, Nitschke L, Burke JF. 1989. Aminoglycoside suppression at UAG, UAA and UGA codons in Escherichia coli and human tissue culture cells. Mol Gen Genet 217:411-418. (Pubitemid 19165012)
94. Martin R. 1994. On the relationship between preferred termination codon contexts and nonsense suppression in human cells. Nucleic Acids Res 22:15-19. (Pubitemid 24157427)
95. Mattis VB, Rai R, Wang J, Chang CW, Coady T, Lorson CL. 2006. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet 120:589-601. (Pubitemid 44669792)
96. Mattis VB, Ebert AD, Fosso MY, Chang CW, Lorson CL. 2009a. Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Hum Mol Genet 18:3906-3913.
97. Mattis VB, Fosso MY, Chang CW, Lorson CL. 2009b. Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA. BMC Neurosci 10:142.
98. McCaughan KK, Brown CM, Dalphin ME, Berry MJ, Tate WP. 1995. Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc Natl Acad Sci USA 92:5431-5435.
99. McCracken GH Jr, Chrane DF, Thomas ML. 1971. Pharmacologic evaluation of gentamicin in newborn infants. J Infect Dis 124 Suppl:S214-S2 23.
100. Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR. 2008. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 61:859-868. (Pubitemid 351426071)
101. Moazed D, Noller HF. 1986. Transfer RNA shields specific nucleotides in 16S ribosomal RNA from attack by chemical probes. Cell 47:985-994. (Pubitemid 17005071)
102. Mühlemann O, Eberle AB, Stalder L, Zamudio Orozco R. 2008. Recognition and elimination of nonsense mRNA. Biochim Biophys Acta 1779:538-549.
103. Nowak KJ, Davies KE. 2004. Duchenne muscular dystrophy and dystrophin: Pathogenesis and opportunities for treatment. EMBO Rep 5:872-876. (Pubitemid 350011231)
104. Nudelman I, Rebibo-Sabbah A, Shallom-Shezifi D, Hainrichson M, Stahl I, Ben-Yosef T, Baasov T. 2006. Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations. Bioorg Med Chem Lett 16:6310-6315. (Pubitemid 44709899)
105. Nudelman I, Rebibo-Sabbah A, Cherniavsky M, Belakhov V, Hainrichson M, Chen F, Schacht J, Pilch DS, Ben-Yosef T, Baasov T. 2009. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 52:2836-2845.
106. Nudelman I, Glikin D, Smolkin B, Hainrichson M, Belakhov V, Baasov T. 2010. Repairing faulty genes by aminoglycosides: Development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 18:3735-3746.
107. Ogle JM, Brodersen DE, Clemons WM Jr, Tarry MJ, Carter AP, Ramakrishnan V. 2001. Recognition of cognate transfer RNA by the 30S ribosomal subunit. Science 292:897-902. (Pubitemid 32422480)
108. Ogle JM, Murphy FV, Tarry MJ, Ramakrishnan V. 2002. Selection of tRNA by the ribosome requires a transition from an open to a closed form. Cell 111:721-732. (Pubitemid 35446316)
109. Ohnishi T, Yamashita A, Kashima I, Schell T, Anders KR, Grimson A, Hachiya T, Hentze MW, Anderson P, Ohno S. 2003. Phosphorylation of hUPF1 induces formation of mRNA surveillance complexes containing hSMG-5 and hSMG-7. Mol Cell 12:1187-1200. (Pubitemid 37487927)
110. Pal M, Ishigaki Y, Nagy E, Maquat LE. 2001. Evidence that phosphorylation of human Upfl protein varies with intracellular location and is mediated by a wortmannin-sensitive and rapamycin-sensitive PI 3-kinase-related kinase signaling pathway. RNA 7:5-15. (Pubitemid 32381924)
111. Pape T, Wintermeyer W, Rodnina MV. 2000. Conformational switch in the decoding region of 16S rRNA during aminoacyl-tRNA selection on the ribosome. Nat Struct Biol 7:104-107. (Pubitemid 30082505)
112. Parker J. 1989. Errors and alternatives in reading the universal genetic code. Microbiol Rev 53:273-298.
113. Peltz SW, Welch EM, Jacobson A, Trotta CR, Naryshkin N, Sweeney HL, Bedwell DM. 2009. Nonsense suppression activity of PTC124 (ataluren). Proc Natl Acad Sci USA 106:E64; author reply E65.
114. Peske F, Rodnina MV, Wintermeyer W. 2005. Sequence of steps in ribosome recycling as defined by kinetic analysis. Mol Cell 18:403-412. (Pubitemid 40704755)
115. Phillips-Jones MK, Hill LS, Atkinson J, Martin R. 1995. Context effects on misreading and suppression at UAG codons in human cells. Mol Cell Biol 15:6593-6600.
116. Pisarev AV, Skabkin MA, Pisareva VP, Skabkina OV, Rakotondrafara AM, Hentze MW, Hellen CU, Pestova TV. 2010. The role of ABCE1 in eukaryotic posttermination ribosomal recycling. Mol Cell 37:196-210.
117. Politano L, Nigro G, Nigro V, Piluso G, Papparella S, Paciello O, Comi LI. 2003. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 22:15-21. (Pubitemid 36966404)
118. Qian Y, Guan MX. 2009. Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation. Antimicrob Agents Chemother 53:4612-4618.
119. Rebibo-Sabbah A, Nudelman I, Ahmed ZM, Baasov T, Ben-Yosef T. 2007. In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome. Hum Genet 122:373-381. (Pubitemid 47616545)
120. Recht MI, Douthwaite S, Puglisi JD. 1999. Basis for prokaryotic specificity of action of aminoglycoside antibiotics. EMBO J 18:3133-3138. (Pubitemid 29255621)
121. Reiter RJ, Tan DX, Korkmaz A, Fuentes-Broto L. 2011. Drug-mediated ototoxicity and tinnitus: Alleviation with melatonin. J Physiol Pharmacol 62:151-157.
122. Riff LJ, Jackson GG. 1971. Pharmacology of gentamicin in man. J Infect Dis 124 Suppl:S98-105.
123. Rodnina MV, Wintermeyer W. 2001. Fidelity of aminoacyl-tRNA selection on the ribosome: Kinetic and structural mechanisms. Annu Rev Biochem 70:415-435. (Pubitemid 32662216)
124. Rogan MP, Stoltz DA, Hornick DB. 2011. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 139:1480-1490.
125. Rowe SM, Sloane P, Tang LP, Backer K, Mazur M, Buckley-Lanier J, Nudelman I, Belakhov V, Bebok Z, Schwiebert E, Baasov T, Bedwell DM. 2011. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. J Mol Med 89:1149-1161.
126. Ruusala T, Ehrenberg M, Kurland CG. 1982. Is there proofreading during polypeptide synthesis? EMBO J 1:741-745.
127. Salas-Marco J, Bedwell DM. 2004. GTP hydrolysis by eRF3 facilitates stop codon decoding during eukaryotic translation termination. Mol Cell Biol 24:7769-7778. (Pubitemid 39121500)
128. Salas-Marco J, Bedwell DM. 2005. Discrimination between defects in elongation fidelity and termination efficiency provides mechanistic insights into translational readthrough. J Mol Biol 348:801-815. (Pubitemid 40544383)
129. Schiffelers R, Storm G, Bakker-Woudenberg I. 2001. Liposomeencapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother 48:333-344. (Pubitemid 32898802)
130. Scholte BJ, Davidson DJ, Wilke M, De Jonge HR. 2004. Animal models of cystic fibrosis. J Cyst Fibros 3 Suppl 2:183-190. (Pubitemid 40045596)
131. Scolnick E, Tompkins R, Caskey T, Nirenberg M. 1968. Release factors differing in specificity for terminator codons. Proc Natl Acad Sci USA 61:768-774.
132. Sermet-Gaudelus I, Leal T, Deboeck CEA. 2008. PTC124 induces CFTR full-length production and activity in children with nonsensemutation-mediated CF. J Cyst Fibros 7:S22.
133. Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, Miller NL, Constantine S, Reha A, Ajayi T, Elfring GL, Miller LL. 2010. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 182:1262-1272.
134. Sha SH, Schacht J. 2000. Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is a potential protectant. Hear Res 142:34-40. (Pubitemid 30169125)
135. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. 1989. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 244:1578-1580. (Pubitemid 19189735)
136. Smith AL, Daum RS, Siber GR, Scheifele DW, Syriopoulou VP. 1988. Gentamicin penetration into cerebrospinal fluid in experimental Haemophilus influenzae meningitis. Antimicrob Agents Chemother 32:1034-1039.
137. Smyth AR, Bhatt J. 2012. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2:CD002009.
138. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O, Koller BH. 1992. An animal model for cystic fibrosis made by gene targeting. Science 257:1083-1088.
139. Swan SK, Kohlhepp SJ, Kohnen PW, Gilbert DN, Bennett WM. 1991. Long-term protection of polyaspartic acid in experimental gentamicin nephrotoxicity. Antimicrob Agents Chemother 35:2591-2595.
140. Tan L, Narayan SB, Chen J, Meyers GD, Bennett MJ. 2011. PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation. J Inherit Metab Dis 34:443-447.
141. Tauris J, Christensen EI, Nykjaer A, Jacobsen C, Petersen CM, Ovesen T. 2009. Cubilin and megalin co-localize in the neonatal inner ear. Audiol Neurootol 14:267-278.
142. Thibault N, Grenier L, Simard M, Bergeron MG, Beauchamp D. 1995. Protection against gentamicin nephrotoxicity by daptomycin in nephrectomized rats. Life Sci 56:1877-1887.
143. Thompson RC, Stone PJ. 1977. Proofreading of the codon-anticodon interaction on ribosomes. Proc Natl Acad Sci USA 74:198-202.
144. Usuki F, Yamashita A, Higuchi I, Ohnishi T, Shiraishi T, Osame M, Ohno S. 2004. Inhibition of nonsense-mediated mRNA decay rescues the phenotype in Ullrich's disease. Ann Neurol 55:740-744. (Pubitemid 38544337)
145. Usuki F, Yamashita A, Kashima I, Higuchi I, Osame M, Ohno S. 2006. Specific inhibition of nonsense-mediated mRNA decay components, SMG-1 or Upf1, rescues the phenotype of Ullrich disease fibroblasts. Mol Ther 14:351-360. (Pubitemid 44184971)
146. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu P. 2009. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106:18825-18830.
147. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA. 2011. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 108:18843-18848.
148. Vecsler M, Ben Zeev B, Nudelman I, Anikster Y, Simon AJ, Amariglio N, Rechavi G, Baasov T, Gak E. 2011. Ex vivo treatment with a novel synthetic aminoglycoside NB54 in primary fibroblasts from Rett syndrome patients suppresses MECP2 nonsense mutations. PLoS ONE 6:e20733.
149. Vogel Z, Zamir A, Elson D. 1969. The possible involvement of peptidyl transferase in the termination step of protein biosynthesis. Biochemistry 8:5161-5168.
150. Wagner KR, Hamed S, Hadley DW, Gropman AL, Burstein AH, Escolar DM, Hoffman EP, Fischbeck KH. 2001. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 49:706-711. (Pubitemid 32530236)
151. Wang D, Belakhov V, Kandasamy J, Baasov T, Li SC, Li YT, Bedwell DM, Keeling KM. 2012. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Mol Genet Metab 105:116-125.
152. Weixlbaumer A, Jin H, Neubauer C, Voorhees RM, Petry S, Kelley AC, Ramakrishnan V. 2008. Insights into translational termination from the structure of RF2 bound to the ribosome. Science 322:953-956.
153. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. 2007. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87-91. (Pubitemid 46685839)
154. Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E. 2000. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161:860-865. (Pubitemid 30171743)
155. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E. 2003. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349:1433-1441. (Pubitemid 37211058)
156. Wilschanski M, Armoni S, Yaacov YEA. 2008. PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF. J Cyst Fibros 7:S22.
157. Wilschanski M, Kerem E. 2011. New drugs for cystic fibrosis. Expert Opin Investig Drugs 20:1285-1292.
158. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, Yaakov Y, Pugatsch T, Pugatch T, Cohen-Cymberknoh M, Miller NL, Reha A, Northcutt VJ, Hirawat S, Donnelly K, Elfring GL, Ajayi T, Kerem E. 2011. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 38:59-69.
159. Wohlgemuth I, Pohl C, Mittelstaet J, Konevega AL, Rodnina MV. 2011. Evolutionary optimization of speed and accuracy of decoding on the ribosome. Philos Trans R Soc Lond, B, Biol Sci 366:2979-2986.
160. Woodworth JR, Nyhart EH, Wolny JD, Brier GL, Black HR. 1994. Tobramycin and daptomycin disposition when coadministered to healthy volunteers. J Antimicrob Chemother 33:655-659. (Pubitemid 24110884)
161. Wraith JE. 2005. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6:489-506. (Pubitemid 40521085)
162. Yamashita A, Kashima I, OHNO S. (2006). Role of SMG-1-mediated phosphorylation of Upf1 in NMD. In: Maquat LE, (ed). Nonsense-Mediated mRNA Decay. Georgetown: Landes Bioscience.
163. Youngman EM, McDonald ME, Green R. 2008. Peptide release on the ribosome: Mechanism and implications for translational control. Annu Rev Microbiol 62:353-373.
164. Yukihara M, Ito K, Tanoue O, Goto K, Matsushita T, Matsumoto Y, Masuda M, Kimura S, Ueoka R. 2011. Effective drug delivery system for duchenne muscular dystrophy using hybrid liposomes including gentamicin along with reduced toxicity. Biol Pharm Bull 34:712-716.
165. Zaher HS, Green R. 2009. Quality control by the ribosome following peptide bond formation. Nature 457:161-166.
166. Zarraga IG, Zhang L, Stump MR, Gong Q, Vincent GM, Zhou Z. 2011. Nonsense-mediated mRNA decay caused by a frameshift mutation in a large kindred of type 2 long QT syndrome. Heart Rhythm 8:1200-1206.
167. Zavialov AV, Buckingham RH, Ehrenberg M. 2001. A posttermination ribosomal complex is the guanine nucleotide exchange factor for peptide release factor RF3. Cell 107:115-124. (Pubitemid 32972042)
168. Zavialov AV, Hauryliuk VV, Ehrenberg M. 2005. Splitting of the posttermination ribosome into subunits by the concerted action of RRF and EF-G. Mol Cell 18:675-686. (Pubitemid 40804803)
169. Zhang L, Button B, Gabriel SE, Burkett S, Yan Y, Skiadopoulos MH, Dang YL, Vogel LN, McKay T, Mengos A, Boucher RC, Collins PL, Pickles RJ. 2009. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol 7:e1000155.